Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance.
Market Samachar is a news aggregator. This article was originally published by mint - markets. Tap the button above to read the full story on their site.